Valuing Reductions in Fatal Illness Risks: Implications of Recent Research.
about
Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis.Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington StateEconomics in "Global Health 2035": a sensitivity analysis of the value of a life year estimates.Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds.
P2860
Valuing Reductions in Fatal Illness Risks: Implications of Recent Research.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Valuing Reductions in Fatal Illness Risks: Implications of Recent Research.
@en
type
label
Valuing Reductions in Fatal Illness Risks: Implications of Recent Research.
@en
prefLabel
Valuing Reductions in Fatal Illness Risks: Implications of Recent Research.
@en
P2860
P356
P1433
P1476
Valuing Reductions in Fatal Illness Risks: Implications of Recent Research.
@en
P2093
Lisa A Robinson
P2860
P356
10.1002/HEC.3214
P407
P577
2015-06-30T00:00:00Z